European Pharmaceutical Review

JUNE 28, 2023

million by 2030, growing at a compound annual growth rate (CAGR) of 5.57 Growth of the pharmaceutical and biotechnology industries, plus the need for accurate and precise analytical tools in drug development and quality control are influencing factors. percent in 2022, with a market value of $1,858.82

Drug Development 98

Drug Development Compounding 98

European Pharmaceutical Review

AUGUST 17, 2022

According to a recent report , the global formulation development outsourcing market size should grow to $61.4 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2 percent from its 2022 value of $35.1 Pharmaceutical companies globally are significantly investing in R&D.

Compounding 96

Compounding Pharmaceutical Companies Pharmaceutical Companies Drug Development 96

European Pharmaceutical Review

DECEMBER 16, 2022

According to a report by Future Market Insights (FMI), the global Alzheimer’s therapeutics market is expected to grow at a compound annual growth rate (CAGR) of 9.3 billion worldwide in 2022. percent, and driven largely by collaboration of existing players, reach $6.8 billion by 2032.

Compounding 98

Compounding Immunization Immunity Drug Development 98

European Pharmaceutical Review

JULY 25, 2023

billion in 2022. A compound annual growth rate (CAGR) growth of 5.9 Complex compounds offer targeted, effective medicines and typically outperform small molecule APIs. A report from Market Research Biz has illustrated that the small molecule active pharmaceutical ingredient (API) market is expected value around $284.7

Compounding 97

Compounding Drug Development Generic Medicine Diabetes 97

Express Pharma

APRIL 3, 2023

The diagnosed prevalent cases of gastric, breast, and bladder cancers in China are expected to increase at a compound annual growth rate (CAGR) of 2.6 per cent, and 3 per cent, respectively, between 2022 and 2028. These companies have active research and development collaborations with various local players worldwide.

Chemotherapy 98

Chemotherapy Compounding Drug Development 98

European Pharmaceutical Review

JUNE 28, 2022

According to recent market research , the global market for biopharmaceutical bioseparation systems, estimated to value $13 billion in 2022, is projected to grow to $19.6 billion by 2026, achieving a compound annual growth rate (CAGR) of 13.2 percent CAGR between 2022 and 2026.

Dosage 111

Dosage Compounding Drug Development 111

RX Note

JULY 8, 2023

Introduction Drug development is an expensive and lengthy process , taking about 2-3 billion dollars and over 10 years to discover and develop a drug to commercialization. Drug Development Timeline Discovery and Development Research for a new drug begins in the laboratory.

Drug Development 52

Drug Development Compounding 52

Express Pharma

AUGUST 8, 2023

The dyslipidemia market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan) is forecast to increase at a compound annual growth rate (CAGR) of 10.8 billion in 2022 to $15.53 per cent from $5.56 The post Dyslipidemia market to grow to $15.53

Compounding 97

Compounding Drug Development 97

Express Pharma

JUNE 5, 2023

GlobalData’s latest report, ‘Myelofibrosis: Eight-Market Drug Forecast and Market Analysis,’ reveals that the MF market will grow from $2.39 billion in 2031 across the 8MM, registering a compound annual growth rate (CAGR) of 1.9 billion in 2021 to $2.89 per cent, driven by the approvals of nine pipeline agents.

Drug Development 97

Drug Development Biosimilars Compounding 97

Pharmaceutical Technology

DECEMBER 5, 2022

Cannabinoid receptors are a popular therapeutic target for cannabinoid-based drugs in the treatment of pain, neurological disorders and inflammation, according to GlobalData’s Pharma Intelligence Centre Drugs database. Cannabinoid-based drugs are derived from compounds found in the cannabis plant.

Controlled Substances 98

Controlled Substances Compounding Immunization Immunity 98

European Pharmaceutical Review

DECEMBER 21, 2022

Organic compounds are arguably the foundation of the pharmaceutical industry. All traditional small molecule pharmaceuticals include carbon building blocks” Organic compounds are arguably the foundation of the pharmaceutical industry. Chem Rev 2022 122 (3), 3637‒3710. ACS Sustain Chem Eng 2022 10 (16), 5148‒5162.

Compounding 97

Compounding Pharmaceutical Manufacturing Pharmaceutical Companies Pharmaceutical Companies 97

European Pharmaceutical Review

OCTOBER 6, 2022

billion by the end of 2022 and $10.7 billion in 2032, propelled by a compound annual growth rate (CAGR) of 11.3 They detect and characterise different types of bacteria, which is useful for drug development and other important research areas. .

Compounding 98

Compounding Drug Development 98

pharmaphorum

DECEMBER 5, 2022

Pluvicto becomes the first PSMA-targeted intravenous radioligand therapy – combining a targeting compound or ligand with a therapeutic radionuclide or radioactive particle (in this case, lutetium-177) – to demonstrate clinical benefit in mCRPC patients before receiving taxane-based chemotherapy.

Chemotherapy 59

Chemotherapy Labelling Compounding Drug Development 59

European Pharmaceutical Review

APRIL 3, 2024

As such, the sector is expected to grow at a compounded annual growth rate (CAGR) of 6.5 percent between 2022-2030. This is contributing to a more streamlined and efficient approach to drug development, according to the report. percent between 2022-2030.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Biosimilars Compounding 52

pharmaphorum

MARCH 14, 2022

Novel Compounds and Treatments for Pain: Opioids and the Alternatives. Drug development. Exploratory development. Interactive Workshop on Friday 6 May 2022 on… Molecular and Cellular Pathophysiology of Pain Resolution. Sponsored by: CHDR. Anaesthesia and Pain Management. • CNS clinical trials. •

Compounding 52

Compounding Drug Development 52

European Pharmaceutical Review

FEBRUARY 21, 2023

“Cannabis is becoming more widely accepted around the world and is being widely researched by many international organisations for medicinal purposes,” acknowledged Dr Jaap Venema, the United States Pharmacopeia (USP)’s Chief Science Officer in September 2022.

Pharmaceutical Companies 132

Pharmaceutical Companies Pharmaceutical Companies Compounding Drug Development 132

Pharmaceutical Technology

JANUARY 23, 2023

These developments were compounded by Lilly’s announcement that it has discontinued development of mirikizumab for psoriasis in April of last year. The Role of Master Protocols in Pediatric Drug Development. Ther Innov Regul Sci.

Labelling 59

Labelling Compounding Drug Development 59

pharmaphorum

JANUARY 24, 2022

Exploring the Impact of Machine Learning and Artificial Intelligence in Drug Development from Discovery to Healthcare. SMi Group is proud to present its 3rd Annual AI in Drug Discovery Conference , taking place on the 14th and 15th March 2022 in London, UK. Sponsored by: Optibrium.

Compounding 52

Compounding Drug Development 52

pharmaphorum

DECEMBER 2, 2022

These problems are compounded with site-level concerns about protocol complexity, staffing shortages, low patient interest, and budgetary constraints — leaving sponsors to question how to plan trials that deliver against timeline commitments to support launch goals. March 2022. Getz, Kenneth. Pharmaceutical Outsourcing. 2016;18(1).

Compounding 98

Compounding Drug Development 98

European Pharmaceutical Review

JULY 4, 2024

4,6 Five patent issues that European biosimilar developers should consider before entering the US market Quality control of the botanical drug substances was one of the critical factors that led to barricades during the development of Veregen and Mytesi. 2022 [cited 2024May]. BMB Reports. 2017;50(3):111–6.

Drug Development 103

Drug Development Biosimilars Documentation Labelling 103

Pharmaceutical Technology

AUGUST 12, 2022

billion by the end of 2022. By 2028, the market is expected to reach $25 billion, with a compound annual growth rate (CAGR) of 46.6%. There are a total of 124 companies involved in CAR-T cell drug development for this indication. Overall, the global CAR-T cell market for all indications was worth $1.7

Immunity 52

Immunity Immunization Chemotherapy Compounding 52

European Pharmaceutical Review

JANUARY 16, 2023

This Q&A covers the key developments in pharmaceutical microbiology in 2022, featuring insight from pharmaceutical microbiology experts: Dr Tim Sandle, Head of Microbiology, Bio Products Laboratory Limited. Regulation, particularly Annex 1, was identified as a key focus for 2022.

Vaccines 128

Vaccines Research Laboratories Documentation Compounding 128

Express Pharma

AUGUST 2, 2023

Centhaquine, a first-in-class drug developed by Pharmazz India, a majority-owned subsidiary of Pharmazz, has received approval from the US-FDA to enter phase 3 clinical trials in the US and the EU. It is a compound that acts via a unique mechanism of action.

Compounding 94

Compounding Hospitals Drug Development 94

European Pharmaceutical Review

JANUARY 29, 2024

17 Accelerating drug development The first issue of 2023 , 18 dealt with accelerating drug development. The FDA, in its “Overview of Major Quality Deficiencies and Approaches Available in GDUFA III” (generic drug user fee amendments) identified dissolution testing as one of its major quality deficiencies during 2023.

Drug Development 111

Drug Development Vaccines Compounding 111

PharmaShots

MARCH 14, 2023

The article focuses on challenges faced in drug development, government incentive programs, grants, and various therapies used to diagnose or treat rare diseases. How challenging is the drug development plan Drug development plans for rare diseases can be circuitous, resulting in fewer participation from companies.

Drug Development 40

Drug Development Immunization Immunity Compounding 40

Pharmaceutical Technology

MARCH 22, 2023

According to the GlobalData report Contract Injectable Packaging Trends in the Bio/Pharma Industry , more than half (55%) of FDA drug approvals in 2021 were accounted for by injectables. In addition, in 2022, non-new molecular entity (NME) injectables approvals were the highest they have been for the last decade.

Packaging 52

Packaging Compounding Pharmaceutical Companies Pharmaceutical Companies 52

Express Pharma

JULY 10, 2024

Over the past few years, several emerging trends such as pricing and inflation, technology implementation, focus on sustainability practices, the transition toward personalised and next-generation therapeutics, and innovative healthcare delivery models, are compounding the complexities within manufacturing and supply chain operations.

Vaccines 96

Vaccines Drug Development Process Improvement Biosimilars 96

Pharmaceutical Technology

DECEMBER 9, 2022

Rankings 2022. M&A – Commended PRODUCT LAUNCHES – Commended RESEARCH AND DEVELOPMENT – Commende d. Solvias is a Swiss-based pharmaceutical company focused on contract research, development and manufacturing. Solvias is well equipped to provide stability testing for all stages of drug development.

Vaccines 52

Vaccines Biosimilars Compounding Packaging 52

European Pharmaceutical Review

MARCH 4, 2024

Indeed, in 2022, biologics constituted 40 percent of all US Food and Drug Administration (FDA) approved drugs, projecting a compound annual growth rate (CAGR) of 9.5 Anna has a medical degree and a postgraduate degree in healthcare management and is an expert in all stages of drug development. Drug Deliv.

Vaccines 98

Vaccines Immunization Immunity Compounding 98

Pharmaceutical Technology

DECEMBER 16, 2022

Pharmaceutical Technology lists some of the top events in the tropical disease arena in 2022. As per the WHO’s 2022 malaria report , 63,000 malaria deaths were attributed to Covid-19-caused disruptions to services from 2019–21. Novel therapeutics and vaccines for malaria.

Drug Development 105

Drug Development Vaccines Clinical Pharmacology Compounding 105

PharmaShots

APRIL 3, 2023

at current exchange rates In Oct 2022, the acquisition was initiated and the transaction is expected to be adjusted per share by $0.07 in success-based development milestones & holds rights to all other assets derived from enfumafungin along with leading the execution & costs of the ongoing clinical studies of ibrexafungerp.

Biosimilars 40

Biosimilars Diabetes Compounding Hospitals 40